Abstract
Genomic sequencing of healthy newborns to screen for medically important genetic information has long been anticipated but data around downstream medical consequences are lacking. Among 159 infants randomized to the sequencing arm in the BabySeq Project, an unanticipated monogenic disease risk (uMDR) was discovered in 18 (11.3%). We assessed uMDR actionability by visualizing scores from a modified ClinGen Actionability SemiQuantitative Metric and tracked medical outcomes in these infants for 3-5 years. All uMDRs scored as highly actionable (mean 9, range: 7-11 on a 0-12 scale) and had readily available clinical interventions. In 4 cases, uMDRs revealed unsuspected genetic etiologies for existing phenotypes, and in the remaining 14 cases provided risk stratification for future surveillance. In 8 cases, uMDRs prompted screening for multiple at-risk family members. These results suggest that actionable uMDRs are more common than previously thought and support ongoing efforts to evaluate population-based newborn genomic screening.
Competing Interest Statement
Dr. Green has received compensation for advising the following companies: AIA, Allelica, Embryome, Genomic Life, Grail, Humanity, Kneed Media, Meenta, OptumLabs, Plumcare, Verily, VinBigData; and is co-founder of Genome Medical. Dr. Shah is a member of the Scientific Advisory Board for Neuberg Center for Genomic Medicine Ms. Genetti has received compensation for consulting for Kate Therapeutics Dr. Yu has consulted and received compensation or honoraria from Eisai, BioMarin, GeneTx, Takeda, and Alnylam, and serves on the Scientific Advisory Board for several not-for-profit rare disease foundations. BZ has recieved compensation for consulting for Novartis Gene Therapies. Dr. Lebo is employed by a not-for-profit, fee-for-service clinical laboratory at Mass General Brigham offering genomic screening. Dr. Agrawal is a member of the Scientific Advisory Board for GeneDx and Illumina, Inc. Dr. McGuire is a member of the board of the Greenwall Foundation and is on the Scientific Advisory Board for Danaher Life Sciences, Geisinger Research, and the Morgridge Institute for Research. Dr. Rehm is a member of the Scientific Advisory Board for Genome Medical and is employed as the medical and clinical laboratory director for a fee-for service laboratory offering genomic sequencing at the Broad Institute of MIT and Harvard. Dr. Holm is a member of the Scientific Advisory Board for Biomarin for vosoritide. Dr. Beggs has received funding from the NIH, MDA (USA), AFM Telethon, Alexion Pharmaceuticals Inc., Audentes Therapeutics Inc., Avidity Biosciences, Dynacure SAS, and Pfizer Inc. He has consulted and received compensation or honoraria from Asklepios BioPharmaceutical Inc, Audentes Therapeutics, Biogen, F. Hoffman-La Roche AG, GLG Inc, Guidepoint Global, and Kate Therapeutics, and holds equity in Kinea Biosciences and Kate Therapeutics.
Clinical Trial
NCT02422511
Funding Statement
This study was funded by NIH grants HD077671 and TR003201.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Boards of Mass General Brigham and Boston Childrens Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
